GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanopharmaceutics Inc (OTCPK:TGRP) » Definitions » Notes Receivable

Nanopharmaceutics (Nanopharmaceutics) Notes Receivable : $0.00 Mil (As of Sep. 2018)


View and export this data going back to 2016. Start your Free Trial

What is Nanopharmaceutics Notes Receivable?

Nanopharmaceutics's Notes Receivable for the quarter that ended in Sep. 2018 was $0.00 Mil.


Nanopharmaceutics Notes Receivable Historical Data

The historical data trend for Nanopharmaceutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanopharmaceutics Notes Receivable Chart

Nanopharmaceutics Annual Data
Trend Dec15 Dec16 Dec17
Notes Receivable
- - -

Nanopharmaceutics Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Nanopharmaceutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Nanopharmaceutics Notes Receivable Related Terms

Thank you for viewing the detailed overview of Nanopharmaceutics's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanopharmaceutics (Nanopharmaceutics) Business Description

Traded in Other Exchanges
N/A
Address
14120 NW 126 Terrace, Alachua, FL, USA, 32615
Nanopharmaceutics Inc is a clinical-stage specialty pharmaceutical company. It is engaged in developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. The company's pipeline products include Triapine, Ammonium Tetrathiomolybdate, and Aza-TdC targeting cancer; NanoBUP, PRX-3140, NP-18-2, and NP-18-3 targeting CNS; and Ramoplanin and NanoDOX.